Cadence Design Systems, Inc. (NASDAQ:CDNS) shares edged up 0.80% to $31.54 on Monday. Cadence Design Systems, Inc. (NASDAQ:CDNS) announced the Xcelium™ Parallel Simulator, the industry’s first production-ready third generation simulator. It is based on innovative multi-core parallel computing technology, enabling systems-on-chip (SoCs) to get to market faster. On average, customers can achieve 2X improved single-core performance and more than 5X improved multi-core performance versus previous generation Cadence simulators. The Cadence® Xcelium simulator is production proven, having been deployed to early adopters across mobile, graphics, server, consumer, internet of things (IoT) and automotive projects.
Technical Stock Analysis
Shares outstanding are recorded as 274.22 and total shares floated are 274.22. Current ratio which is the relationship between current assets and current liabilities, indicating the liquidity of a business is calculated as 1.20. Company’s distance from 20 day simple moving average is 8.14% and distance from 50-Day simple moving average is 16.29%.
Best time to invest in stock market is when things are on odd side, and it’s not easy how to pick stocks. By reviewing stock prices from the stock market history of the company and examining its analysts ratings can give an investment picture with updated information of stock which helps investors to make investing decision. Stock has got OUTPERFORM rating from 1 analyst of Thomson Reuters, 4 analysts given HOLD rating to the stock and 0 given UNDERPERFORM rating. Analyst’s mean target price for CDNS is $29.67 while analysts mean recommendation is 2.30.
Cadence Design Systems, Inc. (NASDAQ:CDNS) yearly performance is 45.82% and net profit margin is 11.20%. Annual EPS Growth of past 5 years is 21.20%. Company price to earnings (P/E) ratio, which measures the relationship between the earnings of a company and its stock price, is calculated as 45.25. The current share price indicate that stock is 0.80% away from its one year high and is moving 48.56% ahead of its 52-week low.
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced financial results for the fourth quarter and full year ended December 31, 2016. In a separate press release issued earlier today, BioCryst announced positive results from an interim analysis of its APeX-1 clinical trial of BCX7353 for the treatment of HAE attacks. For the three months ended December 31, 2016, total revenues increased to $9.0 million from $4.6 million in the fourth quarter of 2015. This increase, compared to the fourth quarter of 2015, resulted from higher peramivir royalty revenue and inventory sales to Seqirus, and was slightly offset by lower collaborative revenue in the fourth quarter of 2016.
On 27 February 2017, BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) shares moved to $5.51 after starting the day at $4.20. Stock has got OUTPERFORM rating from 4 analysts of Thomson Reuters, 3 analysts given HOLD rating to the stock and 0 given UNDERPERFORM rating. Analyst’s mean target price for BCRX is $8.10 while analysts mean recommendation is 2.30.